Evidence map›Paper›PMID 31971976›Full record

ArticlePloS one2020

MicroRNA expression and DNA methylation profiles do not distinguish between primary and recurrent well-differentiated liposarcoma.

Melissa Vos, Ruben Boers, Anne L M Vriends, Joachim Boers, Patricia F van Kuijk, Winan J van Houdt, Geert J L H van Leenders, Michal Wagrodzki, Wilfred F J van IJcken, Joost Gribnau and 4 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 58% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 2 countries.

Melissa VosDepartment of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.ORCID 0000-0001-6238-8643
Ruben BoersDepartment of Developmental Biology, Erasmus University Medical Center, Rotterdam, the Netherlands.
Anne L M VriendsDepartment of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
Joachim BoersDepartment of Developmental Biology, Erasmus University Medical Center, Rotterdam, the Netherlands.
Patricia F van KuijkDepartment of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
Winan J van HoudtDepartment of Surgical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Geert J L H van LeendersDepartment of Pathology, Erasmus University Medical Center, Rotterdam, the Netherlands.
Michal WagrodzkiDepartment of Pathology, Maria Skłodowska-Curie Institute-Oncology Center, Warsaw, Poland.
Wilfred F J van IJckenCenter for Biomics, Erasmus University Medical Center, Rotterdam, the Netherlands.
Joost GribnauDepartment of Developmental Biology, Erasmus University Medical Center, Rotterdam, the Netherlands.
Dirk J GrünhagenDepartment of Surgical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
Cornelis VerhoefDepartment of Surgical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
Stefan SleijferDepartment of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
Erik A C WiemerDepartment of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.ORCID 0000-0002-0673-7236
Erasmus MC Cancer Institute · NLErasmus MC · NLThe Maria Sklodowska-Curie National Research Institute of Oncology · PLThe Netherlands Cancer Institute · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Approximately one-third of the patients with well-differentiated liposarcoma (WDLPS) will develop a local recurrence. Not much is known about the molecular relationship between the primary tumor and the recurrent tumor, which is important to reveal potential drivers of recurrence. Here we investigated the biology of recurrent WDLPS by comparing paired primary and recurrent WDLPS using microRNA profiling and genome-wide DNA methylation analyses. In total, 27 paired primary and recurrent WDLPS formalin-fixed and paraffin-embedded tumor samples were collected. MicroRNA expression profiles were determined using TaqMan® Low Density Array (TLDA) cards. Genome-wide DNA methylation and differentially methylated regions (DMRs) were assessed by methylated DNA sequencing (MeD-seq). A supervised cluster analysis based on differentially expressed microRNAs between paired primary and recurrent WDLPS did not reveal a clear cluster pattern separating the primary from the recurrent tumors. The clustering was also not based on tumor localization, time to recurrence, age or status of the resection margins. Changes in DNA methylation between primary and recurrent tumors were extremely variable, and no consistent DNA methylation changes were found. As a result, a supervised clustering analysis based on DMRs between primary and recurrent tumors did not show a distinct cluster pattern based on any of the features. Subgroup analysis for tumors localized in the extremity or the retroperitoneum also did not yield a clear distinction between primary and recurrent WDLPS samples. In conclusion, microRNA expression profiles and DNA methylation profiles do not distinguish between primary and recurrent WDLPS and no putative common drivers could be identified.

Indexed as

Gene Expression Regulation, NeoplasticAdultAgedCluster AnalysisDNA MethylationFemaleGenetic HeterogeneityHumansLiposarcomaMaleMicroRNAsMiddle AgedNeoplasm Recurrence, LocalPrincipal Component AnalysisMicroRNAs

Identifiers

PMID31971976
PMCPMC6977735
OpenAlexW3003132453

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.